Medications

New treatment option for nonalcoholic fatty liver disease

A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) ...

Diseases, Conditions, Syndromes

TGen-led study finds link between gene and severe liver damage

Researchers have found that a gene known as AEBP1 may play a central role in the development, severity and potential treatment of liver disease, according to a study by Temple University, the Geisinger Obesity Institute and ...

Diseases, Conditions, Syndromes

T2DM is risk factor for liver fibrosis progression in NAFLD

Type 2 diabetes mellitus (T2DM) is a risk factor for progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), according to a study published online May 21 in the Journal of Gastroenterology ...

Diseases, Conditions, Syndromes

Novel biomarkers for noninvasive diagnosis of NAFLD-related fibrosis

With an estimated 25% of people worldwide affected by nonalcoholic fatty liver disease (NAFLD), there is a large unmet need for accurate, noninvasive measures to enhance early diagnosis and screening of hepatic fibrosis. ...

page 1 from 4